Sino Biopharmaceutical Limited (1177.HK) stock analysis

In our weekly check, Sino Biopharmaceutical Limited is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 18 pass, warnings: 4, red flags: 2.

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited is a Healthcare company (Medical - Pharmaceuticals) based in Hong Kong, listed on HKSE as 1177.HK.

What our checks show for 1177.HK

Red flags

• The net margin fell by 47.3 points over 5 years, to 7.1%: the company keeps less of each sale as profit.
• The stock has fallen as much as 78% from a peak. Would you have held through that?

Warning signs

• Net profit fell 2.1% a year over the last 3 years.
• The net margin is only 7.1%: little room if costs rise.
• The price swings a lot: 41.1% annual volatility. Expect large ups and downs.
• The stock is still below its previous peak.

Strengths

• The gross margin is 82.4% and has risen by 2.3 points: pricing power is holding.
• Operating cash flow is 3.89x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 37.2% a year over the next years.
• Analysts expect the net margin to improve by 3.9 points from today's 7.1%.
• Free cash flow is 22.5% of revenue: cash for dividends, buybacks or growth.
• A large company: market value $11.35 billion.

Similar companies

6618.HK · SOBI.ST · RADL3.SA · RPRX · REC.MI · CORT

Questions

What grade does Sino Biopharmaceutical Limited (1177.HK) have?

In our weekly check, Sino Biopharmaceutical Limited is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 18 pass, warnings: 4, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 1177.HK stock?

This week's biggest flags for Sino Biopharmaceutical Limited: Margins falling, Deep past fall, Weak profit growth. In total 6 of 24 checks show a warning or a red flag.

What does Sino Biopharmaceutical Limited do?

Sino Biopharmaceutical Limited is a Healthcare company (Medical - Pharmaceuticals) based in Hong Kong, listed on HKSE as 1177.HK.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis